Table 1.
Baseline demographic characteristics of the study population (Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease score ≥ 22.5 at baseline).
| Overall (n = 100) | Adalimumab (n = 51) | Placebo (n = 49) | |
|---|---|---|---|
| Age, mean (SD) | 37.9 (12.2) | 37.6 (11.9) | 38.1 (12.7) |
| Female, n (%) | 62 (62.0) | 33 (64.7) | 29 (59.2) |
| CD duration, mean (SD) | 10.1 (8.2) | 10.4 (8.1) | 9.7 (8.2) |
| CD location, n (%) | |||
| Colon | 35 (35.0) | 12 (23.5) | 23 (46.9) |
| Ileocolonic | 65 (65.0) | 39 (76.5) | 26 (53.1) |
| CDAI score, mean (SD) | 324.8 (71.4) | 328.7 (68.3) | 320.7 (74.9) |
| SES-CD score, median (IQR) | 19 (13.5-24) | 17 (13-23) | 20 (16-25) |
| MM-SES-CD score, median (IQR) | 37.3 (30.5-50) | 36.5 (30-50.5) | 39.5 (30.5-49.5) |
| Prior anti-TNF use, n (%) | 52 (52.0) | 24 (47.1) | 28 (57.1) |
| Concomitant corticosteroid use, n (%) | 31 (31.0) | 14 (27.5) | 17 (34.7) |